Leech bionic Hirudin fusion protein prodrug loaded microneedles for long-term inhibition of thrombosis

The clinical use of anticoagulant drugs for thrombosis is limited by short half-life and bleeding risk, requiring frequent administration and close monitoring. Here, inspired by leech mouthparts, we present a hirudin-based fusion protein prodrug incorporated with microneedles (MNs) for long-term antithrombotic therapy to achieve a simplified dosing regimen, continuous protection, and on-demand antithrombotic bioactivity recovery. Genetic-engineered anticoagulant prodrugs are precisely customized by fusing hirudin to elastin-like polypeptides with adjustable assembly characteristics. The introduction of elastin-like polypeptides can shield the biological activity of hirudin, drive the self-assembly of fusion proteins, and prolong their half-life in vivo. The fusion protein prodrugs circulate in the blood as sentinels and accumulate in the thrombus site with the assistance of the clot-targeted motif. Under the catalysis of FXa during thrombosis, the fusion protein prodrugs adaptively restore anticoagulant activity to inhibit thrombus formation. Notably, the assembled prodrugs were integrated into an MN matrix made of silk fibroin and chitosan through photopolymerization for long-term controlled release and facile self-administration. It was proved that the bionic MNs conveniently provide long protection against thrombosis without increasing bleeding events. These excellent performances indicate that the bionic MN patch has broad application prospects in thrombosis and related diseases.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

The clinical use of anticoagulant drugs for thrombosis is limited by short half-life and bleeding risk, requiring frequent administration and close monitoring.

Explore how this research connects to clinical practice

More peer-reviewed studies in Drug Development.

• Novel Leech Antimicrobial Peptides — Hirunipins — Kumar et al. (2025)
• Medicinal Leech Genome Assembly — Anticoagulant Gene Catalog — Kvist et al. (2020)
• BRIGHT-4 Trial — Bivalirudin vs Heparin by BMI — BRIGHT-4 Investigators (2025)
• RE-LY Trial — Dabigatran vs Warfarin in Atrial Fibrillation — Connolly SJ et al. (2009)
• Hirudin Disrupts Breast Cancer CTC Clusters — Anti-Metastatic Potential — Research team (2025) (2025)
• Novel CRA Protein from Hirudo medicinalis — Complement Regulation — Research team (2025) (2025)
• Hirunipin-2 — Second-Generation Leech Antimicrobial Peptide — Kumar et al. (2025)
• Effects of hirudotherapy on liver functions, lipid profile, and insulin sensitivity in rats with metabolic syndrome — Bilden A et al. (2026)
• Hirudotherapy in Medicine and Dentistry — Jha K et al. (2015)
• Medicinal leech therapy (hirudotherapy): a brief overview — Singh A (2010)